Could a daily 'Good Bacteria' capsule speed up recovery after sepsis?
NCT ID NCT07295353
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a daily capsule of pasteurized Akkermansia muciniphila, a type of beneficial gut bacteria, can help adults recover after being treated for sepsis in the ICU. Fifty participants will take either the supplement or a placebo for 56 days. Researchers will check safety and measure changes in gut bacteria and immune markers from stool and blood samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pasteurized Akkermansia muciniphila (a beneficial gut bacteria) taken as a daily capsule
What this could lead to
If it works, this could point toward a simple, safe supplement to help people recover their gut health and immune function after a serious ICU stay for sepsis.
What could go wrong
This is a very early, small study (50 people) testing safety and gut bacteria changes, not whether it actually improves recovery. The supplement may have no effect or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••